Atty. Dkt. No. 018733-1236

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David M. GOLDENBERG

Title: POLYSPECIFIC IMMUNOCONJUGATES AND ANTIBODY COMPOSITES FOR TARGETING THE MULTIDRUG RESISTANT PHENOTYPE

Appl. No.: Unasssigned

Filing Date: 09/30/2003

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicant submits herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent applications Serial No. 10/206,361, filed 07/29/2002, and 08/629,388, filed 04/08/1996. As provided in 37 CFR §1.98(d), copies of the documents are not being provided because they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Oct 8, 2003

By Michael M. Dixon Reg No. 34,717

FOLEY & LARDNER
Customer Number: 22428
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

for Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: September 29, 2003

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	Unassigned
Filing Date	09/30/2003
First Named Inventor	David M. GOLDENBERG
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	018733-1236

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	B1	5,005,588		RUBIN	04/1991	
	B2	5,258,372		LEVY	11/1993	
	B3	5,332,567		GOLDENBERG	07/1994	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	B4	EP	0 569 141			11/1993		
	B5	CA	2,093,866			10/1993		
	B6	WO	92/08802			05/1992		
	B7	WO	93/19094			09/1993		
	B8	WO	93/02105			02/1993		
	B9	WO	93/25700			12/1993		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	B10	BRAY et al., "Malaria Chemotherapy: Resistance to Quinoline Containing Drugs in Plasmodium Falciparum," FEMS Microbiol. Lett. (1993) 113:1-8.	
	B11	CALABRESI, "Drug Resistance: Lonidamine," PPO Updates (June 1994), 8(6):1-15.	
	B12	CHEN et al., "Internal Duplication and Homology with Bacterial Transport Proteins in the mdr1 (P-Glycoprotein) Gene from Multidrug-Resistant Human Cells," Cell (November 7, 1986) 47:318-389.	
	B13	CHILDS et al., "The MDR Superfamily of Genes and its Biological Implications," Important Advances in Oncology, De Vita et al. (Eds.) pp. 21-36 (J.P. Lippincott 1994).	
	B14	DALTON et al., "Immunohistochemical Detection and Quantitation of P-Glycoprotein in Multiple Drug-Resistance Human Myeloma Cells: Association With Level of Drug Resistance and Drug Accumulation," Blood (February 15, 1989) 73:747-752.	
	B15	DEYOUNG, "Biotech Companies and Drug Firms Take Steps to Combat Drug-Resistant Bacteria," Genetic Engineering News (July 14, 1994) 14:1, 14.	
	B16	DOIGE et al., "ATP-Dependent Transport Systems in Bacterial and Humans: Relevance to Cystic Fibrosis and Multidrug Resistance," Annu. Rev. Microbiol. (1993), 47:291-319.	
	B17	DURRANT et al., "Sensitivity of Newly Established Colorectal Cell Lines to Cytotoxic Drugs and Monoclonal Antibody Drug Conjugates," Br. J. Cancer (1987), 56:772-726.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: September 29, 2003

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	Unassigned
Filing Date	09/30/2003
First Named Inventor	David M. GOLDENBERG
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	018733-1236

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	B18	EFFERTH et al., "Antibody-Directed Therapy of Multidrug-Resistant Tumor Cells," Med. Oncol. & Tumor Pharmacother. (1992), 9(1)11-19.	
	B19	ENDICOTT et al., "The Biochemistry of P-Glycoprotein-Mediated Multidrug Resistance," Annu. Rev. Biochem. (1989) 58:137-171.	
	B20	FITZGERALD et al., "A Monoclonal Antibody-Pseudomonas Toxin Conjugate That Specifically Kills Multidrug-Resistant Cells.	
	B21	GEORGES et al., "Modulation of ATP and Drug Binding By Monoclonal Antibodies Against P-Glycoprotein," J. Cell Physiol. (1991), 148:479-484.	
	B22	GOLDSTEIN et al., "Expression of a Multidrug Resistance Gene in Human Cancers," J. Natl. Cancer Inst. (January 18, 1989), 81:116-124.	
	B23	GRINIUS et al., "A Staphylococcal Multidrug Resistance Gene Product is a Member of a New Protein Family," Plasmid (1992), 27:119-129.	
	B24	HAMADA et al., "Functional Role for the 170- to 180-kDa Glycoprotein Specific to Drug-Resistant Tumor Cells As Revealed by Monoclonal Antibodies," Proc. Natl. Acad. Sci. USA (October 1986) 83:7785-7789.	
	B25	IWAHASHI et al., "Specific Targeting and Killing Activities of Anti-P-Glycoprotein Monoclonal Antibody MRK 16 Directed Against Intrinsically Multidrug-Resistant Human Colorectal Carcinoma Cell Lines in the Nude Mouse Model," Cancer Research (November 15, 1993), 53:5475-5482.	
	B26	NEYFAKH et al., "Efflux-Mediated Multidrug Resistance in Bacillus Subtilis: Similarities and Dissimilarities With the Mammalian System," Proc. Natl. Acad. Sci. USA (June 1991), 88:4781-4785.	
	B27	NOONAN et al., "Quantitative Analysis of MDR1 (multidrug resistance) Gene Expression in Human Tumors By Polymerase Chain Reaction," Proc. Natl. Acad. Sci. USA (September 1990), 87:7160-7164.	
	B28	PEARSON et al., "Reversal of Drug Resistance in a Human Colon Cancer Xenograft Expressing MDR1 Complementary DNA by in Vivo Administration of MRK-16 Monoclonal Antibody," J. Natl. Cancer Inst. (1991) 83:1386-1391.	
	B29	RITTMANN-GRAUER et al., " Reversal of Finca Alkaloid Resistance by Anti-Glycoprotein Monoclonal Antibody HYB-241 in a Human Tumor Xenograft," Cancer Res. (April 1, 1992), 52:1810-1816.	
	B30	SARKADI et al., "Interaction of Bioactive Hydrophobic Peptides With the Human Multidrug Transporter," The FASEB Journal (July 1994), 8:766:770.	
	B31	SCHNEIDER et al., "P-Glycoprotein Expression in Treated and Untreated Human Breast Cancer," Br. J. Cancer (1989), 60:815-818.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: September 29, 2003

(use as many sheets as necessary)

Sheet	3	of	3

Complete if Known	
Application Number	Unassigned
Filing Date	09/30/2003
First Named Inventor	David M. GOLDENBERG
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	018733-1236

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	B32	SHELDON et al., "Sensitivity of Multidrug Resistant KB-C1 Cells to an Antibody-Dextran-Adriamycin Conjugate," Anticancer Research (1989), 9:637-642.	
	B33	TONG et al., "Elimination of Chemoresistant Multiple Myaloma Clonogenic Colony-forming Cells by Combined Treatment with a Plasma Cell-reactive Monoclonal Antibody and a P-Glycoprotein-reactive Monoclonal Antibody," Cancer Res. (September 1, 1989), 49:4829-4834.	
	B34	VAN DUK et al., Bispecific Antibodies Reactive with the Multidrug-Resistance-Related Glycoprotein and CD3 Induce Lysis of Multidrug-Resistant Tumor Cells," Int. J. Cancer (1989) 44:738-743.	
	B35	VOLM et al., "Detection of Multidrug Resistant Phenotype in Human Tumorus by Monoclonal Antibodies and the Streptavidin-Biotinylated Phycoerythrin Complex Methods," Eur. J. Cancer Clin. Oncol. (1989) 23(4):743-749.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.